The US FDA has dropped a requirement that prescribers and patients enroll in a monitoring network to use Nplate and Promacta, among other changes. News Alerts
More evidence to support the first-line use of erlotinib in nonsmall-cell lung cancer (NSCLC) testing positive for EGFR mutations. br / iMedscape Medical News/i